346 related articles for article (PubMed ID: 28806136)
1. Harnessing OLIG2 function in tumorigenicity and plasticity to target malignant gliomas.
Kosty J; Lu F; Kupp R; Mehta S; Lu QR
Cell Cycle; 2017 Sep; 16(18):1654-1660. PubMed ID: 28806136
[TBL] [Abstract][Full Text] [Related]
2. Lineage-Restricted OLIG2-RTK Signaling Governs the Molecular Subtype of Glioma Stem-like Cells.
Kupp R; Shtayer L; Tien AC; Szeto E; Sanai N; Rowitch DH; Mehta S
Cell Rep; 2016 Sep; 16(11):2838-2845. PubMed ID: 27626655
[TBL] [Abstract][Full Text] [Related]
3. Olig2-Dependent Reciprocal Shift in PDGF and EGF Receptor Signaling Regulates Tumor Phenotype and Mitotic Growth in Malignant Glioma.
Lu F; Chen Y; Zhao C; Wang H; He D; Xu L; Wang J; He X; Deng Y; Lu EE; Liu X; Verma R; Bu H; Drissi R; Fouladi M; Stemmer-Rachamimov AO; Burns D; Xin M; Rubin JB; Bahassi EM; Canoll P; Holland EC; Lu QR
Cancer Cell; 2016 May; 29(5):669-683. PubMed ID: 27165742
[TBL] [Abstract][Full Text] [Related]
4. Quantitative analysis of mitotic Olig2 cells in adult human brain and gliomas: implications for glioma histogenesis and biology.
Rhee W; Ray S; Yokoo H; Hoane ME; Lee CC; Mikheev AM; Horner PJ; Rostomily RC
Glia; 2009 Apr; 57(5):510-23. PubMed ID: 18837053
[TBL] [Abstract][Full Text] [Related]
5. OLIG2 maintenance is not essential for diffuse intrinsic pontine glioma cell line growth but regulates tumor phenotypes.
Liao Y; Luo Z; Deng Y; Zhang F; Rao R; Wang J; Xu L; Kumar SS; Sengupta S; DeWire-Schottmiller M; Berry K; Garrett M; Fouladi M; Drissi R; Lu QR
Neuro Oncol; 2021 Jul; 23(7):1183-1196. PubMed ID: 33539525
[TBL] [Abstract][Full Text] [Related]
6. Oncostatin-M differentially regulates mesenchymal and proneural signature genes in gliomas via STAT3 signaling.
Natesh K; Bhosale D; Desai A; Chandrika G; Pujari R; Jagtap J; Chugh A; Ranade D; Shastry P
Neoplasia; 2015 Feb; 17(2):225-37. PubMed ID: 25748242
[TBL] [Abstract][Full Text] [Related]
7. Subtyping of gliomas of various WHO grades by the application of immunohistochemistry.
Popova SN; Bergqvist M; Dimberg A; Edqvist PH; Ekman S; Hesselager G; Ponten F; Smits A; Sooman L; Alafuzoff I
Histopathology; 2014 Feb; 64(3):365-79. PubMed ID: 24410805
[TBL] [Abstract][Full Text] [Related]
8. Prognostic impact of glioblastoma stem cell markers OLIG2 and CCND2.
Bouchart C; Trépant AL; Hein M; Van Gestel D; Demetter P
Cancer Med; 2020 Feb; 9(3):1069-1078. PubMed ID: 31568682
[TBL] [Abstract][Full Text] [Related]
9. Fatal correlation between YAP1 expression and glioma aggressiveness: clinical and molecular evidence.
Guichet PO; Masliantsev K; Tachon G; Petropoulos C; Godet J; Larrieu D; Milin S; Wager M; Karayan-Tapon L
J Pathol; 2018 Oct; 246(2):205-216. PubMed ID: 30009411
[TBL] [Abstract][Full Text] [Related]
10. LGR5 promotes tumorigenicity and invasion of glioblastoma stem-like cells and is a potential therapeutic target for a subset of glioblastoma patients.
Xie Y; Sundström A; Maturi NP; Tan EJ; Marinescu VD; Jarvius M; Tirfing M; Jin C; Chen L; Essand M; Swartling FJ; Nelander S; Jiang Y; Uhrbom L
J Pathol; 2019 Feb; 247(2):228-240. PubMed ID: 30357839
[TBL] [Abstract][Full Text] [Related]
11. A Sequentially Priming Phosphorylation Cascade Activates the Gliomagenic Transcription Factor Olig2.
Zhou J; Tien AC; Alberta JA; Ficarro SB; Griveau A; Sun Y; Deshpande JS; Card JD; Morgan-Smith M; Michowski W; Hashizume R; James CD; Ligon KL; Snider WD; Sicinski P; Marto JA; Rowitch DH; Stiles CD
Cell Rep; 2017 Mar; 18(13):3167-3177. PubMed ID: 28355568
[TBL] [Abstract][Full Text] [Related]
12. SHP-2-upregulated ZEB1 is important for PDGFRα-driven glioma epithelial-mesenchymal transition and invasion in mice and humans.
Zhang L; Zhang W; Li Y; Alvarez A; Li Z; Wang Y; Song L; Lv D; Nakano I; Hu B; Cheng SY; Feng H
Oncogene; 2016 Oct; 35(43):5641-5652. PubMed ID: 27041571
[TBL] [Abstract][Full Text] [Related]
13. The cell of origin dictates the temporal course of neurofibromatosis-1 (Nf1) low-grade glioma formation.
Solga AC; Toonen JA; Pan Y; Cimino PJ; Ma Y; Castillon GA; Gianino SM; Ellisman MH; Lee DY; Gutmann DH
Oncotarget; 2017 Jul; 8(29):47206-47215. PubMed ID: 28525381
[TBL] [Abstract][Full Text] [Related]
14. The NF-κB RelB protein is an oncogenic driver of mesenchymal glioma.
Lee DW; Ramakrishnan D; Valenta J; Parney IF; Bayless KJ; Sitcheran R
PLoS One; 2013; 8(2):e57489. PubMed ID: 23451236
[TBL] [Abstract][Full Text] [Related]
15. Novel HSP90 inhibitor NVP-HSP990 targets cell-cycle regulators to ablate Olig2-positive glioma tumor-initiating cells.
Fu J; Koul D; Yao J; Wang S; Yuan Y; Colman H; Sulman EP; Lang FF; Yung WK
Cancer Res; 2013 May; 73(10):3062-74. PubMed ID: 23492364
[TBL] [Abstract][Full Text] [Related]
16. The oligodendroglial lineage marker OLIG2 is universally expressed in diffuse gliomas.
Ligon KL; Alberta JA; Kho AT; Weiss J; Kwaan MR; Nutt CL; Louis DN; Stiles CD; Rowitch DH
J Neuropathol Exp Neurol; 2004 May; 63(5):499-509. PubMed ID: 15198128
[TBL] [Abstract][Full Text] [Related]
17. A novel drug conjugate, NEO212, targeting proneural and mesenchymal subtypes of patient-derived glioma cancer stem cells.
Jhaveri N; Agasse F; Armstrong D; Peng L; Commins D; Wang W; Rosenstein-Sisson R; Vaikari VP; Santiago SV; Santos T; Chen L; Schönthal AH; Chen TC; Hofman FM
Cancer Lett; 2016 Feb; 371(2):240-50. PubMed ID: 26683773
[TBL] [Abstract][Full Text] [Related]
18. Id2 mediates oligodendrocyte precursor cell maturation arrest and is tumorigenic in a PDGF-rich microenvironment.
Havrda MC; Paolella BR; Ran C; Jering KS; Wray CM; Sullivan JM; Nailor A; Hitoshi Y; Israel MA
Cancer Res; 2014 Mar; 74(6):1822-32. PubMed ID: 24425046
[TBL] [Abstract][Full Text] [Related]
19. Expression of CD133 and CD44 in glioblastoma stem cells correlates with cell proliferation, phenotype stability and intra-tumor heterogeneity.
Brown DV; Filiz G; Daniel PM; Hollande F; Dworkin S; Amiridis S; Kountouri N; Ng W; Morokoff AP; Mantamadiotis T
PLoS One; 2017; 12(2):e0172791. PubMed ID: 28241049
[TBL] [Abstract][Full Text] [Related]
20. The transcription factor Olig2 is important for the biology of diffuse intrinsic pontine gliomas.
Anderson JL; Muraleedharan R; Oatman N; Klotter A; Sengupta S; Waclaw RR; Wu J; Drissi R; Miles L; Raabe EH; Weirauch ML; Fouladi M; Chow LM; Hoffman L; DeWire M; Dasgupta B
Neuro Oncol; 2017 Aug; 19(8):1068-1078. PubMed ID: 28339768
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
